

# Walpole

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	27.4	80.2	(50.2-121.4)	Male	21	17.2	122.1	(75.5-186.6)
Female	12	9.8	122.7	(63.4-214.4)	Female	16	12.8	124.5	(71.1-202.2)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	5.3	nc	(nc-nc)	Male	1	4.3	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)	Female	6	3.1	194.2	(70.9-422.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	16	14.8	108.1	(61.8-175.6)
Female	100	93.6	106.8	(86.9-130.0)	Female	9	12.5	72.2	(32.9-137.1)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.8	nc	(nc-nc)	Male	8	10.3	78.0	(33.6-153.6)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	31	36.4	85.2	(57.9-120.9)	Female	18	9.5	189.9	(112.5-300.1)
Female	37	34.1	108.4	(76.3-149.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	7	8.4	83.8	(33.6-172.6)
Male	5	7.1	70.9	(22.8-165.4)	Female	1	8.4	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	96	99.8	96.2	(77.9-117.4)
Male	2	2.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.5	nc	(nc-nc)	Male	10	6.4	156.1	(74.7-287.2)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	3.8	nc	(nc-nc)
Male	26	13.4	194.6	(127.1-285.2)	<b><u>Testis</u></b>				
Female	6	7.7	78.3	(28.6-170.4)	Male	4	3.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	4.2	119.3	(38.4-278.3)	Male	6	4.8	126.2	(46.1-274.7)
Female	0	1.1	nc	(nc-nc)	Female	16	13.9	115.3	(65.9-187.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	9.4	53.3	(17.2-124.4)	Female	22	20.8	105.8	(66.2-160.1)
Female	4	6.9	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	342	359.6	95.1	(85.3-105.7)
Male	4	6.6	nc	(nc-nc)	Female	334	329.6	101.3	(90.8-112.8)
Female	2	2.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	50	49.7	100.6	(74.6-132.6)					
Female	50	46.7	107.0	(79.4-141.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Waltham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	48	60.7	79.0	(58.3-104.8)	Male	33	38.8	85.0	(58.5-119.4)
Female	23	23.5	97.9	(62.0-146.9)	Female	34	32.2	105.7	(73.2-147.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	12.0	49.8	(18.2-108.4)	Male	11	9.4	117.1	(58.4-209.6)
Female	11	10.0	110.5	(55.1-197.8)	Female	5	7.4	67.6	(21.8-157.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	38	33.3	114.1	(80.7-156.6)
Female	233	219.5	106.2	(93.0-120.7)	Female	26	30.2	86.0	(56.1-126.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	9.4	53.0	(17.1-123.8)	Male	28	22.5	124.2	(82.5-179.5)
Female					Female	12	11.2	106.7	(55.1-186.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	57	80.3	71.0	(53.8-92.0)	Female	30	22.7	132.1	(89.1-188.6)
Female	98	81.5	120.3	(97.6-146.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	24	18.4	130.2	(83.4-193.8)
Male	10	15.5	64.4	(30.8-118.4)	Female	20	20.2	98.8	(60.3-152.7)
Female	9	4.5	201.8	(92.1-383.1)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	206	220.2	93.6	(81.2-107.2)
Male	4	6.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	5	4.9	102.1	(32.9-238.2)	Male	12	14.2	84.8	(43.8-148.1)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	11	9.1	120.9	(60.3-216.4)
Male	20	29.3	68.2	(41.6-105.3)	<b><u>Testis</u></b>				
Female	14	18.4	76.3	(41.7-128.0)	Male	12	11.1	108.1	(55.8-188.9)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	7	9.2	75.7	(30.3-156.1)	Male	13	11.1	117.4	(62.4-200.8)
Female	2	2.7	nc	(nc-nc)	Female	33	35.8	92.2	(63.5-129.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	10	21.1	47.4	(22.7-87.2)	Female	47	49.0	95.9	(70.4-127.5)
Female	19	16.5	115.4	(69.4-180.2)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	712	802.0	88.8	(82.4-95.5)
Male	15	14.4	104.0	(58.2-171.6)	Female	807	790.7	102.1	(95.1-109.4)
Female	6	5.4	111.8	(40.8-243.4)					
<b><u>Lung and Bronchus</u></b>									
Male	108	110.1	98.1	(80.5-118.4)					
Female	95	112.5	84.4	(68.3-103.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ware

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	11.9	67.4	(29.0-132.8)	Male	5	7.3	68.7	(22.1-160.3)
Female	2	4.7	nc	(nc-nc)	Female	4	5.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	2.2	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	4	6.3	nc	(nc-nc)
Female	28	41.7	67.2	(44.6-97.1)	Female	6	5.9	100.8	(36.8-219.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.7	nc	(nc-nc)	Male	5	4.4	114.3	(36.8-266.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	21	15.7	134.0	(82.9-204.8)	Female	7	4.3	161.3	(64.6-332.4)
Female	9	16.5	54.4	(24.8-103.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	3.6	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	Female	0	4.1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	36	43.2	83.4	(58.4-115.4)
Male	0	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.8	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.9	nc	(nc-nc)
Male	2	5.6	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	3.5	nc	(nc-nc)	Male	4	1.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.8	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	6.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	4.0	nc	(nc-nc)	Female	8	9.3	86.1	(37.1-169.6)
Female	1	3.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	130	154.5	84.1	(70.3-99.9)
Male	3	2.8	nc	(nc-nc)	Female	109	152.3	71.6	(58.8-86.3)
Female	1	1.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	19	21.4	88.7	(53.4-138.5)					
Female	17	22.0	77.4	(45.1-124.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wareham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	26	27.6	94.3	(61.6-138.2)	Male	11	16.6	66.2	(33.0-118.5)
Female	13	10.0	129.8	(69.1-222.0)	Female	5	12.9	38.8	(12.5-90.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	4.9	nc	(nc-nc)	Male	4	4.2	nc	(nc-nc)
Female	3	4.1	nc	(nc-nc)	Female	2	3.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	10	14.2	70.2	(33.6-129.2)
Female	89	94.3	94.4	(75.8-116.1)	Female	10	12.7	78.8	(37.7-145.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.7	nc	(nc-nc)	Male	9	10.0	89.8	(41.0-170.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	48	36.0	133.2	(98.2-176.6)	Female	10	9.6	104.1	(49.8-191.5)
Female	39	34.0	114.7	(81.5-156.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	9	8.4	107.3	(49.0-203.8)
Male	8	7.1	112.9	(48.6-222.4)	Female	15	8.6	174.7	(97.7-288.2)
Female	1	1.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	100	103.8	96.3	(78.4-117.1)
Male	3	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.6	nc	(nc-nc)	Male	4	6.3	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	3.7	nc	(nc-nc)
Male	18	13.0	138.0	(81.7-218.1)	<b><u>Testis</u></b>				
Female	7	7.9	88.7	(35.5-182.8)	Male	2	2.9	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	8	4.3	187.4	(80.7-369.3)	Male	2	4.3	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	11	13.8	79.8	(39.8-142.8)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	16	9.1	176.7	(100.9-286.9)	Female	22	21.5	102.2	(64.0-154.7)
Female	2	6.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	398	359.7	110.6	(100.0-122.1)
Male	12	6.5	185.8	(95.9-324.6)	Female	335	334.1	100.3	(89.8-111.6)
Female	4	2.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	70	50.6	138.3	(107.8-174.8)					
Female	59	49.1	120.2	(91.5-155.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Warren

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.6	89.7	(28.9-209.3)	Male	0	3.5	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	6	2.6	228.2	(83.3-496.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	23	18.5	124.2	(78.7-186.4)	Female	4	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	7.4	67.3	(21.7-157.0)	Female	1	1.9	nc	(nc-nc)
Female	6	6.3	94.6	(34.6-206.0)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	1.7	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	12	21.4	56.0	(28.9-97.9)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Kidney &amp; Renal Pelvis</u>					Female	0	0.7	nc	(nc-nc)
Male	1	2.8	nc	(nc-nc)	<u>Testis</u>				
Female	3	1.5	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	5	3.0	166.5	(53.7-388.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	1.9	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	46	74.7	61.6	(45.1-82.1)
Male	1	1.4	nc	(nc-nc)	Female	81	64.4	125.8	(99.9-156.4)
Female	0	0.4	nc	(nc-nc)	<u>Lung and Bronchus</u>				
Male	5	10.3	48.8	(15.7-113.8)	Male	5	10.3	48.8	(15.7-113.8)
Female	16	9.0	177.8	(101.6-288.7)	Female	16	9.0	177.8	(101.6-288.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Warwick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	3.0	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.3	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	3.3	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney &amp; Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	11	11.5	95.3	(47.5-170.6)
Male	1	0.2	nc	(nc-nc)	Female	5	9.7	51.4	(16.6-119.9)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	1.5	nc	(nc-nc)					
Female	0	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	2.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	2	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	3	2.5	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	7	8.4	83.2	(33.3-171.3)
Male	0	0.2	nc	(nc-nc)	Female	4	6.6	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	1	1.1	nc	(nc-nc)					
Female	0	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Watertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	49	38.6	126.9	(93.8-167.7)	Male	14	23.2	60.4	(33.0-101.4)
Female	14	16.6	84.3	(46.0-141.4)	Female	20	21.0	95.4	(58.3-147.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	6.9	72.4	(23.3-168.9)	Male	3	5.8	nc	(nc-nc)
Female	7	6.4	109.2	(43.7-225.0)	Female	2	5.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.1	nc	(nc-nc)	Male	16	20.1	79.7	(45.5-129.5)
Female	133	144.0	92.3	(77.3-109.4)	Female	22	20.9	105.5	(66.1-159.7)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	6.0	99.7	(36.4-216.9)	Male	9	13.0	69.2	(31.6-131.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	42	49.7	84.4	(60.8-114.1)	Female	16	15.0	106.3	(60.7-172.7)
Female	48	58.1	82.6	(60.9-109.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	18	11.5	157.2	(93.1-248.4)
Male	7	9.4	74.5	(29.9-153.6)	Female	16	14.5	110.7	(63.2-179.8)
Female	5	3.2	157.8	(50.8-368.1)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	118	132.1	89.3	(73.9-107.0)
Male	6	3.3	181.2	(66.2-394.3)	<b><u>Stomach</u></b>				
Female	4	2.8	nc	(nc-nc)	Male	8	8.9	89.7	(38.6-176.8)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	5	6.6	76.1	(24.5-177.6)
Male	16	17.5	91.3	(52.2-148.4)	<b><u>Testis</u></b>				
Female	17	12.4	137.2	(79.9-219.7)	Male	5	5.8	86.6	(27.9-202.1)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	6	5.6	108.1	(39.5-235.3)	Male	6	6.2	96.4	(35.2-209.9)
Female	1	1.8	nc	(nc-nc)	Female	26	22.2	117.3	(76.6-171.8)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	11	12.7	86.6	(43.2-154.9)	Female	30	31.6	94.8	(64.0-135.4)
Female	9	11.2	80.0	(36.5-151.9)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	444	487.2	91.1	(82.8-100.0)
Male	6	8.5	70.8	(25.8-154.0)	Female	495	533.4	92.8	(84.8-101.3)
Female	2	3.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	63	68.9	91.4	(70.2-116.9)					
Female	70	77.8	89.9	(70.1-113.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wayland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	18	16.4	109.6	(64.9-173.2)	Male	12	10.2	117.7	(60.8-205.7)
Female	3	5.5	nc	(nc-nc)	Female	14	7.6	183.0	(100.0-307.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	3.1	nc	(nc-nc)	Male	4	2.6	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	14	8.7	160.4	(87.6-269.1)
Female	84	57.6	145.8	(116.3-180.5)	Female	9	7.2	125.8	(57.4-238.9)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.3	nc	(nc-nc)	Male	5	6.3	78.8	(25.4-183.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	21	21.9	96.0	(59.4-146.7)	Female	7	5.7	122.8	(49.2-252.9)
Female	19	19.1	99.6	(59.9-155.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	5.1	98.8	(31.8-230.6)
Male	1	4.3	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	62	62.7	98.9	(75.9-126.8)
Male	2	1.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.9	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	2.1	nc	(nc-nc)
Male	4	8.1	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	4.6	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	2.6	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	15	8.5	176.0	(98.4-290.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	5.5	nc	(nc-nc)	Female	12	13.0	92.2	(47.6-161.1)
Female	7	3.9	180.6	(72.3-372.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	203	218.0	93.1	(80.8-106.9)
Male	2	4.1	nc	(nc-nc)	Female	222	195.0	113.9	(99.4-129.9)
Female	1	1.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	23	30.3	76.0	(48.1-114.0)					
Female	25	27.3	91.7	(59.3-135.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Webster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	22	20.6	106.6	(66.8-161.3)	Male	9	12.4	72.5	(33.1-137.7)
Female	9	8.2	109.5	(49.9-207.8)	Female	2	10.2	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	3.8	159.5	(58.2-347.2)	Male	3	3.1	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	8	10.8	74.0	(31.8-145.7)
Female	68	71.5	95.1	(73.9-120.6)	Female	15	10.4	144.5	(80.8-238.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	2.8	176.0	(56.7-410.8)	Male	7	7.3	95.8	(38.4-197.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	31	27.0	114.9	(78.1-163.1)	Female	6	7.5	80.3	(29.3-174.7)
Female	35	29.2	119.8	(83.4-166.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	11	6.2	176.8	(88.1-316.4)
Male	9	5.2	174.2	(79.5-330.8)	Female	3	7.2	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	62	72.3	85.8	(65.8-110.0)
Male	3	1.6	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	3.3	nc	(nc-nc)
Male	8	9.6	83.2	(35.8-164.0)	<b><u>Testis</u></b>				
Female	6	6.1	98.3	(35.9-213.9)	Male	1	2.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	3	10.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	13	6.9	188.0	(100.0-321.4)	Female	17	15.7	108.0	(62.9-173.0)
Female	9	5.7	157.9	(72.0-299.8)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	269	263.4	102.1	(90.3-115.1)
Male	1	4.7	nc	(nc-nc)	Female	254	264.0	96.2	(84.7-108.8)
Female	3	1.9	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	37	36.9	100.3	(70.6-138.3)					
Female	33	38.1	86.6	(59.6-121.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wellesley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	16	29.8	53.7	(30.7-87.2)	Male	32	18.3	174.8	(119.5-246.8)
Female	8	11.3	70.9	(30.5-139.6)	Female	18	15.3	118.0	(69.9-186.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	5.6	nc	(nc-nc)	Male	5	4.6	107.6	(34.7-251.1)
Female	2	4.9	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	10	15.8	63.3	(30.3-116.4)
Female	118	108.6	108.7	(89.9-130.1)	Female	14	14.6	95.7	(52.3-160.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	4.4	nc	(nc-nc)	Male	13	11.3	115.3	(61.4-197.3)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	28	39.7	70.6	(46.9-102.0)	Female	13	11.2	116.3	(61.9-198.9)
Female	38	39.6	95.9	(67.9-131.7)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	13	9.1	142.6	(75.8-243.8)
Male	2	7.7	nc	(nc-nc)	Female	10	9.8	102.0	(48.8-187.5)
Female	3	2.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	128	110.7	115.6	(96.4-137.4)
Male	3	2.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	2.3	nc	(nc-nc)	Male	3	6.9	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	4.4	nc	(nc-nc)
Male	15	14.5	103.7	(58.0-171.0)	<b><u>Testis</u></b>				
Female	5	8.9	56.0	(18.0-130.7)	Male	5	3.2	158.1	(51.0-369.0)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	4.6	nc	(nc-nc)	Male	6	4.9	122.8	(44.8-267.3)
Female	1	1.3	nc	(nc-nc)	Female	22	16.6	132.6	(83.1-200.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	16	10.1	158.0	(90.2-256.6)	Female	24	24.3	98.9	(63.4-147.2)
Female	9	8.1	111.3	(50.8-211.3)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	355	391.2	90.8	(81.6-100.7)
Male	8	7.3	109.5	(47.1-215.8)	Female	365	384.6	94.9	(85.4-105.2)
Female	3	2.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	19	54.2	35.0	(21.1-54.7)					
Female	27	54.1	49.9	(32.9-72.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wellfleet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	5.0	217.9	(108.6-389.9)	Male	3	2.8	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	6	2.0	298.6	(109.0-649.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.1	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	20	15.2	131.8	(80.5-203.5)	Female	2	2.0	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.6	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	6	6.4	93.2	(34.0-202.9)	Female	1	1.6	nc	(nc-nc)
Female	2	5.6	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	1.5	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	31	17.2	180.2	(122.4-255.8)
Male	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	0.6	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.6	nc	(nc-nc)	Female	6	3.5	173.7	(63.4-378.1)
Female	1	1.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	75	61.7	121.5	(95.6-152.3)
Male	1	1.1	nc	(nc-nc)	Female	60	54.0	111.2	(84.9-143.1)
Female	1	0.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	6	9.0	67.0	(24.5-145.9)					
Female	8	8.1	98.8	(42.6-194.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wendell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	5	3.4	149.0	(48.0-347.7)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	4	3.7	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Kidney &amp; Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	14	12.8	109.1	(59.6-183.0)
Male	0	0.3	nc	(nc-nc)	Female	10	10.1	98.6	(47.2-181.3)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.5	nc	(nc-nc)					
Female	1	1.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wenham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	5.2	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	4	1.8	nc	(nc-nc)	Female	7	2.4	296.9	(118.9-611.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	0.9	531.1	(171.2-1239.5)	Male	0	0.8	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	20	16.6	120.6	(73.6-186.2)	Female	2	2.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	5	6.7	74.8	(24.1-174.5)	Female	1	1.7	nc	(nc-nc)
Female	11	6.1	180.6	(90.0-323.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	1	1.6	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	19	18.1	104.9	(63.1-163.9)
Male	2	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	0.7	nc	(nc-nc)
Male	1	2.4	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.7	nc	(nc-nc)	Female	6	3.7	163.7	(59.8-356.2)
Female	1	1.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	61	65.8	92.7	(70.9-119.1)
Male	1	1.2	nc	(nc-nc)	Female	74	59.6	124.3	(97.6-156.0)
Female	1	0.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	10	9.4	106.8	(51.1-196.5)					
Female	6	8.6	69.8	(25.5-151.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	9.1	65.8	(24.0-143.1)	Male	4	5.9	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	Female	5	3.8	130.6	(42.1-304.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.8	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	11	5.1	216.3	(107.8-387.0)
Female	32	28.0	114.5	(78.3-161.6)	Female	4	3.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.1	nc	(nc-nc)	Male	1	3.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	7	12.1	57.6	(23.1-118.7)	Female	3	2.8	nc	(nc-nc)
Female	5	10.6	47.2	(15.2-110.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	2.8	181.1	(58.4-422.6)
Male	2	2.3	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	20	32.4	61.8	(37.7-95.5)
Male	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.2	nc	(nc-nc)
Male	8	4.5	179.7	(77.4-354.0)	<b><u>Testis</u></b>				
Female	2	2.3	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	3.2	nc	(nc-nc)	Female	8	6.2	130.0	(56.0-256.1)
Female	3	2.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	104	120.1	86.6	(70.7-104.9)
Male	1	2.2	nc	(nc-nc)	Female	93	99.7	93.3	(75.3-114.3)
Female	0	0.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	17	16.4	103.6	(60.3-165.9)					
Female	15	14.4	104.5	(58.4-172.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	10	9.4	106.4	(50.9-195.6)	Male	6	5.6	108.0	(39.4-235.1)
Female	7	3.6	193.0	(77.3-397.7)	Female	2	4.4	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	1.6	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
Female	27	32.0	84.5	(55.7-122.9)	Female	4	4.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	1.2	nc	(nc-nc)	Male	3	3.3	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	8	12.2	65.4	(28.1-128.8)	Female	2	3.3	nc	(nc-nc)
Female	11	12.7	86.8	(43.3-155.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	2.8	nc	(nc-nc)
Male	6	2.4	254.7	(93.0-554.3)	Female	3	3.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	33	33.6	98.2	(67.6-138.0)
Male	2	0.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.5	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.4	nc	(nc-nc)
Male	8	4.3	185.2	(79.7-365.0)	<b><u>Testis</u></b>				
Female	2	2.7	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.4	nc	(nc-nc)	Male	5	1.4	350.5	(113.0-818.0)
Female	0	0.4	nc	(nc-nc)	Female	5	4.4	114.3	(36.8-266.8)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	3.1	nc	(nc-nc)	Female	8	7.2	111.5	(48.0-219.7)
Female	1	2.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	119	119.8	99.4	(82.3-118.9)
Male	2	2.1	nc	(nc-nc)	Female	100	116.4	85.9	(69.9-104.5)
Female	0	0.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	17	16.9	100.6	(58.5-161.0)					
Female	19	17.2	110.8	(66.7-173.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## West Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	6	5.3	113.3	(41.4-246.7)	Male	2	3.1	nc	(nc-nc)
Female	0	2.6	nc	(nc-nc)	Female	0	2.9	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.2	nc	(nc-nc)	Male	5	2.7	184.7	(59.5-431.0)
Female	16	20.5	78.1	(44.6-126.8)	Female	0	3.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	7	6.9	100.9	(40.4-207.8)	Female	4	2.2	nc	(nc-nc)
Female	10	9.8	101.9	(48.8-187.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	1.6	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	5	2.4	211.5	(68.2-493.6)
Female	0	0.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	19	17.8	106.8	(64.3-166.8)
Male	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	1.2	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	2	1.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	1.7	nc	(nc-nc)	Female	4	4.4	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	64	65.5	97.7	(75.2-124.7)
Male	0	1.2	nc	(nc-nc)	Female	59	78.9	74.8	(56.9-96.4)
Female	0	0.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	9	9.0	100.0	(45.6-189.8)					
Female	7	11.2	62.5	(25.1-128.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.9	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	3	1.3	nc	(nc-nc)	Female	9	2.2	413.9	(188.8-785.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	0.9	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	15	15.8	94.9	(53.1-156.5)	Female	1	1.8	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	3	1.9	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	5	5.7	87.8	(28.3-204.9)	Female	2	1.5	nc	(nc-nc)
Female	8	4.5	176.6	(76.0-347.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	1	1.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.4	nc	(nc-nc)	Male	25	16.7	150.0	(97.0-221.4)
Female	0	0.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	1	2.3	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	1	1.5	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.2	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	5	7.4	67.6	(21.8-157.7)	Male	58	57.5	100.8	(76.5-130.3)
Female	7	6.4	108.7	(43.5-224.0)	Female	57	50.6	112.8	(85.4-146.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Springfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	27	34.3	78.8	(51.9-114.6)	Male	18	20.8	86.4	(51.2-136.6)
Female	10	12.6	79.3	(38.0-145.9)	Female	12	16.3	73.6	(38.0-128.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	9	6.3	143.1	(65.3-271.6)	Male	3	5.3	nc	(nc-nc)
Female	4	5.1	nc	(nc-nc)	Female	2	4.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	17	18.0	94.6	(55.1-151.4)
Female	119	116.3	102.3	(84.8-122.4)	Female	16	16.1	99.6	(56.9-161.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	4.6	nc	(nc-nc)	Male	14	12.3	113.8	(62.2-191.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	41	44.9	91.4	(65.6-124.0)	Female	11	12.0	91.9	(45.8-164.5)
Female	37	43.8	84.4	(59.4-116.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	8	10.3	77.3	(33.3-152.3)
Male	12	8.7	138.7	(71.6-242.2)	Female	10	10.9	91.6	(43.9-168.5)
Female	2	2.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	133	123.7	107.5	(90.0-127.4)
Male	1	2.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	3	2.1	nc	(nc-nc)	Male	11	7.9	138.7	(69.2-248.2)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	5	4.9	102.6	(33.1-239.5)
Male	21	16.1	130.3	(80.6-199.1)	<b><u>Testis</u></b>				
Female	11	9.8	112.4	(56.1-201.2)	Male	3	4.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	5.2	nc	(nc-nc)	Male	3	5.6	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	14	17.3	80.8	(44.1-135.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	13	11.5	113.4	(60.3-193.9)	Female	23	26.0	88.4	(56.0-132.6)
Female	7	8.7	80.3	(32.2-165.5)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	424	442.8	95.8	(86.9-105.3)
Male	4	8.0	nc	(nc-nc)	Female	393	417.9	94.0	(85.0-103.8)
Female	4	2.9	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	57	61.9	92.0	(69.7-119.2)					
Female	59	60.5	97.5	(74.2-125.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Stockbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	13	7.1	184.0	(97.9-314.7)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	3.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.6	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.1	nc	(nc-nc)	Female	8	7.8	102.0	(43.9-201.0)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male				
Male	1	1.0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.7	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	0	0.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	4.0	nc	(nc-nc)	Female	21	28.4	74.0	(45.8-113.1)
Female	3	3.5	nc	(nc-nc)	Female	24	24.1	99.6	(63.8-148.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# West Tisbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.8	nc	(nc-nc)	Male	5	1.9	262.5	(84.6-612.6)
Female	0	0.9	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.6	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	13	10.7	121.6	(64.7-208.0)	Female	1	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	3.9	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	4	3.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.8	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	16	11.1	144.5	(82.6-234.7)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male				
Male	0	1.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	2	1.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.8	nc	(nc-nc)	Female	0	2.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	5.2	nc	(nc-nc)	Male	43	39.1	110.0	(79.6-148.1)
Female	5	4.5	109.9	(35.4-256.5)	Female	37	34.7	106.8	(75.2-147.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	17.1	111.2	(66.9-173.7)	Male	13	11.6	111.9	(59.5-191.4)
Female	6	6.7	89.6	(32.7-195.1)	Female	12	9.7	123.1	(63.5-215.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.8	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
Female	3	3.0	nc	(nc-nc)	Female	4	2.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	15	10.0	150.8	(84.3-248.7)
Female	62	66.3	93.5	(71.7-119.9)	Female	6	8.8	68.2	(24.9-148.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.0	nc	(nc-nc)	Male	5	7.0	71.8	(23.1-167.5)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	22	23.6	93.4	(58.5-141.4)	Female	8	6.7	119.7	(51.5-235.8)
Female	22	24.5	89.9	(56.3-136.2)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	11	5.3	209.4	(104.4-374.7)
Male	3	4.5	nc	(nc-nc)	Female	3	5.9	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	66	62.2	106.1	(82.1-135.0)
Male	1	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	3	1.3	nc	(nc-nc)	Male	7	4.1	170.6	(68.4-351.6)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	0	2.8	nc	(nc-nc)
Male	17	8.8	193.5	(112.6-309.8)	<b><u>Testis</u></b>				
Female	3	5.2	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	3	2.7	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	11	11.1	98.9	(49.3-177.0)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	6.3	142.5	(65.0-270.5)	Female	10	14.1	71.1	(34.1-130.8)
Female	2	5.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	241	231.4	104.2	(91.4-118.2)
Male	3	4.4	nc	(nc-nc)	Female	202	233.1	86.7	(75.1-99.5)
Female	2	1.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	23	30.5	75.4	(47.8-113.1)					
Female	27	30.7	88.0	(58.0-128.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	39	43.1	90.5	(64.4-123.8)	Male	23	26.9	85.4	(54.1-128.1)
Female	13	16.3	79.8	(42.4-136.4)	Female	12	21.9	<b>54.9</b>	<b>(28.3-95.8)</b>
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	8	8.4	95.4	(41.1-188.0)	Male	6	6.7	89.8	(32.8-195.5)
Female	7	7.0	100.7	(40.3-207.5)	Female	2	5.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	16	23.4	68.5	(39.1-111.2)
Female	154	152.8	100.8	(85.5-118.0)	Female	28	21.0	133.4	(88.6-192.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	12	6.3	190.0	(98.0-331.9)	Male	13	16.1	80.8	(43.0-138.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	61	57.2	106.6	(81.5-136.9)	Female	21	15.8	133.2	(82.4-203.6)
Female	47	57.3	82.0	(60.2-109.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	13	13.1	99.3	(52.8-169.9)
Male	20	11.0	<b>181.6</b>	<b>(110.9-280.5)</b>	Female	11	14.2	77.7	(38.8-139.1)
Female	2	3.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	151	154.9	97.5	(82.6-114.3)
Male	3	3.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	3	3.2	nc	(nc-nc)	Male	13	10.0	129.5	(68.9-221.5)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	7	6.4	109.5	(43.9-225.6)
Male	20	20.7	96.6	(59.0-149.1)	<b><u>Testis</u></b>				
Female	7	12.7	55.1	(22.1-113.5)	Male	7	6.2	112.0	(44.9-230.8)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	6.5	76.6	(24.7-178.8)	Male	4	7.4	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	20	23.8	84.0	(51.3-129.8)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	14.9	53.6	(23.1-105.6)	Female	38	33.8	112.5	(79.6-154.4)
Female	5	11.6	43.2	(13.9-100.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	540	563.3	95.9	(87.9-104.3)
Male	6	10.4	57.9	(21.1-126.0)	Female	524	548.0	95.6	(87.6-104.2)
Female	4	3.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	89	77.4	115.0	(92.3-141.5)					
Female	75	77.4	96.9	(76.2-121.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	15.5	109.6	(63.8-175.5)	Male	15	12.0	125.0	(69.9-206.2)
Female	4	5.5	nc	(nc-nc)	Female	15	9.9	150.8	(84.3-248.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.1	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	3	3.1	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	7	10.0	70.0	(28.1-144.3)
Female	70	69.1	101.3	(79.0-128.0)	Female	9	7.8	115.1	(52.5-218.6)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	6	3.4	178.1	(65.0-387.6)	Male	5	7.7	64.7	(20.8-150.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	28	22.7	123.3	(81.9-178.2)	Female	10	6.6	151.9	(72.7-279.3)
Female	19	19.8	96.1	(57.8-150.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	5.1	nc	(nc-nc)
Male	2	4.6	nc	(nc-nc)	Female	3	4.7	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	73	66.5	109.9	(86.1-138.1)
Male	0	1.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.4	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	4	2.2	nc	(nc-nc)
Male	11	9.4	117.3	(58.5-209.8)	<b><u>Testis</u></b>				
Female	4	5.1	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	2.8	nc	(nc-nc)	Male	5	3.9	126.9	(40.9-296.1)
Female	0	0.8	nc	(nc-nc)	Female	16	12.7	125.8	(71.9-204.4)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	6.2	144.9	(66.1-275.0)	Female	14	14.9	94.1	(51.4-157.8)
Female	3	4.6	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	244	234.0	104.3	(91.6-118.2)
Male	4	4.8	nc	(nc-nc)	Female	220	222.8	98.8	(86.1-112.7)
Female	2	1.4	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	28	29.6	94.5	(62.8-136.7)					
Female	23	27.5	83.7	(53.1-125.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westhampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	4	6.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	1	2.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	6	6.5	91.9	(33.5-200.0)
Male	1	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	0.2	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	0.4	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.6	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	21	22.4	93.9	(58.1-143.6)
Male	1	0.4	nc	(nc-nc)	Female	11	19.2	57.3	(28.5-102.5)
Female	0	0.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	5	2.9	170.2	(54.9-397.3)					
Female	0	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westminster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	11	7.2	152.5	(76.0-273.0)	Male	3	5.0	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	Female	7	3.8	185.7	(74.4-382.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	1.6	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	6	4.2	142.3	(52.0-309.8)
Female	29	26.8	108.3	(72.5-155.6)	Female	3	3.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.2	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	17	10.1	167.8	(97.7-268.7)	Female	0	2.6	nc	(nc-nc)
Female	6	8.3	72.5	(26.5-157.9)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	28	28.2	99.3	(66.0-143.5)
Female	0	0.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	2	0.7	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	3.9	nc	(nc-nc)	Female	8	5.8	137.5	(59.2-270.9)
Female	2	2.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	1.2	nc	(nc-nc)	Female	8	5.8	137.5	(59.2-270.9)
Female	0	0.3	nc	(nc-nc)	Male	98	100.7	97.3	(79.0-118.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	2.6	nc	(nc-nc)	Female	96	88.4	108.5	(87.9-132.5)
Female	1	1.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	98	100.7	97.3	(79.0-118.6)
Female	0	0.6	nc	(nc-nc)	Female	96	88.4	108.5	(87.9-132.5)
<b><u>Lung and Bronchus</u></b>					<b><u>All Sites / Types</u></b>				
Male	10	13.3	75.0	(35.9-137.9)	Male	98	100.7	97.3	(79.0-118.6)
Female	14	11.6	120.5	(65.8-202.2)	Female	96	88.4	108.5	(87.9-132.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Weston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	9	17.1	52.7	(24.1-100.1)	Male	12	9.9	121.1	(62.5-211.5)
Female	8	5.4	147.8	(63.7-291.3)	Female	6	6.9	86.7	(31.6-188.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.9	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.5	nc	(nc-nc)	Male	5	8.6	57.9	(18.7-135.2)
Female	46	51.2	89.9	(65.8-119.9)	Female	9	6.9	130.3	(59.5-247.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.9	nc	(nc-nc)	Male	1	6.0	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	13	22.3	58.2	(30.9-99.5)	Female	2	5.3	nc	(nc-nc)
Female	15	19.3	77.8	(43.5-128.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	2	5.1	nc	(nc-nc)
Male	1	4.3	nc	(nc-nc)	Female	5	4.7	105.9	(34.1-247.1)
Female	1	1.0	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	70	60.9	115.0	(89.6-145.3)
Male	2	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.8	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	2.1	nc	(nc-nc)
Male	10	7.8	128.1	(61.3-235.6)	<b><u>Testis</u></b>				
Female	5	4.2	119.6	(38.6-279.2)	Male	2	1.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	2.5	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	11	7.2	153.0	(76.3-273.8)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	2	5.6	nc	(nc-nc)	Female	11	11.5	96.0	(47.8-171.8)
Female	3	3.8	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	174	215.7	80.7	(69.1-93.6)
Male	3	3.9	nc	(nc-nc)	Female	163	181.0	90.1	(76.8-105.0)
Female	1	1.2	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	15	30.3	49.5	(27.7-81.7)					
Female	16	25.5	62.8	(35.9-102.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	26	18.9	137.6	(89.8-201.6)	Male	8	12.0	66.7	(28.7-131.4)
Female	10	6.3	158.8	(76.0-292.0)	Female	6	8.8	68.3	(24.9-148.6)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	4	3.6	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.6	nc	(nc-nc)	Male	9	10.2	88.5	(40.4-167.9)
Female	76	64.5	117.8	(92.8-147.4)	Female	6	8.2	73.2	(26.7-159.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.6	nc	(nc-nc)	Male	7	7.5	93.3	(37.4-192.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	21	25.4	82.7	(51.2-126.4)	Female	9	6.5	139.3	(63.6-264.4)
Female	29	21.7	133.9	(89.6-192.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	5.9	102.1	(37.3-222.1)
Male	3	5.1	nc	(nc-nc)	Female	10	5.4	185.4	(88.7-340.9)
Female	2	1.2	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	76	73.8	103.0	(81.1-128.9)
Male	2	1.5	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	3	1.1	nc	(nc-nc)	Male	5	4.4	113.9	(36.7-265.9)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	2.4	nc	(nc-nc)
Male	6	9.4	63.5	(23.2-138.2)	<b><u>Testis</u></b>				
Female	5	5.2	96.1	(31.0-224.2)	Male	4	2.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	5	3.1	163.6	(52.7-381.8)	Male	5	3.3	152.8	(49.2-356.6)
Female	1	0.8	nc	(nc-nc)	Female	16	9.8	162.8	(93.0-264.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	6.3	143.0	(65.2-271.4)	Female	23	14.8	155.3	(98.4-233.1)
Female	6	4.3	138.3	(50.5-301.1)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	266	254.5	104.5	(92.3-117.9)
Male	3	4.8	nc	(nc-nc)	Female	266	221.2	120.3	(106.2-135.6)
Female	2	1.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	37	34.9	105.9	(74.5-146.0)					
Female	29	31.2	92.9	(62.2-133.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Westwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	21.1	80.4	(46.8-128.7)	Male	17	11.9	142.6	(83.0-228.4)
Female	5	7.6	65.4	(21.1-152.5)	Female	22	8.9	245.9	(154.1-372.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	3.5	201.3	(80.6-414.8)	Male	1	3.2	nc	(nc-nc)
Female	3	2.9	nc	(nc-nc)	Female	5	2.4	208.3	(67.1-486.2)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	16	10.5	152.3	(87.0-247.4)
Female	68	66.0	103.0	(80.0-130.6)	Female	13	9.5	136.4	(72.5-233.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.5	nc	(nc-nc)	Male	8	6.9	116.1	(50.0-228.8)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	22	27.1	81.0	(50.8-122.7)	Female	5	6.9	73.0	(23.5-170.3)
Female	33	27.2	121.3	(83.5-170.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	7	6.3	111.8	(44.8-230.3)
Male	2	5.0	nc	(nc-nc)	Female	9	6.7	134.0	(61.1-254.4)
Female	1	1.5	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	70	70.5	99.3	(77.4-125.5)
Male	0	1.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.0	nc	(nc-nc)	Male	3	4.9	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	3.1	nc	(nc-nc)
Male	6	9.2	65.0	(23.7-141.4)	<b><u>Testis</u></b>				
Female	3	5.6	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	3.0	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	9	8.8	102.9	(46.9-195.3)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	6.9	116.8	(50.3-230.1)	Female	10	14.5	69.0	(33.0-126.9)
Female	5	5.2	95.9	(30.9-223.9)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	240	258.5	92.9	(81.5-105.4)
Male	1	4.5	nc	(nc-nc)	Female	268	242.3	110.6	(97.8-124.7)
Female	2	1.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	24	36.8	65.1	(41.7-96.9)					
Female	38	35.3	107.6	(76.1-147.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Weymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	68	62.2	109.2	(84.8-138.5)	Male	36	38.7	93.0	(65.1-128.7)
Female	19	25.1	75.6	(45.5-118.0)	Female	45	32.8	137.1	(100.0-183.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	14	11.8	118.2	(64.6-198.4)	Male	8	9.7	82.8	(35.7-163.2)
Female	10	10.3	97.1	(46.5-178.6)	Female	5	8.0	62.7	(20.2-146.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.9	nc	(nc-nc)	Male	41	33.2	123.6	(88.7-167.7)
Female	228	236.3	96.5	(84.4-109.8)	Female	26	32.0	81.3	(53.1-119.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	12	9.5	125.8	(64.9-219.8)	Male	28	23.2	120.5	(80.1-174.2)
Female					Female	11	11.9	92.2	(46.0-165.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	77	82.1	93.7	(74.0-117.2)	Female	25	24.1	103.9	(67.2-153.3)
Female	86	86.8	99.1	(79.2-122.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	20	19.0	105.4	(64.4-162.8)
Male	26	16.1	161.2	(105.3-236.3)	Female	21	21.7	96.9	(60.0-148.1)
Female	2	4.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	212	232.2	91.3	(79.4-104.4)
Male	6	5.1	118.8	(43.4-258.5)	<b><u>Stomach</u></b>				
Female	4	4.1	nc	(nc-nc)	Male	9	14.4	62.5	(28.5-118.7)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	14	9.6	145.4	(79.4-244.0)
Male	42	30.2	139.1	(100.3-188.1)	<b><u>Testis</u></b>				
Female	27	19.7	136.8	(90.1-199.0)	Male	9	8.2	109.9	(50.2-208.7)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	8	9.6	83.0	(35.7-163.5)	Male	6	10.6	56.6	(20.7-123.3)
Female	2	2.9	nc	(nc-nc)	Female	42	35.4	118.5	(85.4-160.2)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	17	21.0	80.9	(47.1-129.5)	Female	40	52.8	75.7	(54.1-103.1)
Female	13	17.3	75.3	(40.0-128.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	826	820.4	100.7	(93.9-107.8)
Male	10	15.0	66.7	(31.9-122.7)	Female	854	840.3	101.6	(94.9-108.7)
Female	6	5.7	104.8	(38.3-228.0)					
<b><u>Lung and Bronchus</u></b>									
Male	121	114.2	105.9	(87.9-126.5)					
Female	164	121.5	135.0	(115.1-157.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Whately

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.0	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	8	6.4	124.6	(53.7-245.6)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	2	2.7	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.6	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	6	7.3	82.7	(30.2-180.1)
Male	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Kidney &amp; Renal Pelvis</u>					Female	1	0.2	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Testis</u>				
Female	1	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.7	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	18	26.2	68.7	(40.7-108.6)
Male	0	0.5	nc	(nc-nc)	Female	19	21.5	88.5	(53.3-138.3)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	4	3.5	nc	(nc-nc)					
Female	1	2.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Whitman

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	12	12.2	98.1	(50.6-171.4)	Male	8	8.5	93.9	(40.4-185.1)
Female	2	4.5	nc	(nc-nc)	Female	10	7.1	139.9	(67.0-257.4)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	2.8	180.2	(58.1-420.6)	Male	2	2.0	nc	(nc-nc)
Female	4	2.2	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.2	nc	(nc-nc)
Female	46	49.1	93.6	(68.6-124.9)	Female	8	6.1	131.1	(56.4-258.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	2.2	nc	(nc-nc)	Male	6	5.3	113.5	(41.4-247.1)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	17	17.0	100.2	(58.4-160.5)	Female	4	4.9	nc	(nc-nc)
Female	21	15.7	133.8	(82.8-204.6)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	3.9	129.8	(41.8-303.0)
Male	7	3.4	205.8	(82.4-424.0)	Female	4	3.9	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	29	49.1	59.1	(39.5-84.8)
Male	2	1.4	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	2	1.1	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	1.7	nc	(nc-nc)
Male	10	6.6	151.9	(72.7-279.3)	<b><u>Testis</u></b>				
Female	4	3.9	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	2.0	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	6	8.6	69.6	(25.4-151.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	4	4.5	nc	(nc-nc)	Female	6	10.9	55.0	(20.1-119.8)
Female	5	3.4	146.1	(47.1-341.0)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	158	173.0	91.3	(77.6-106.7)
Male	1	3.3	nc	(nc-nc)	Female	178	166.9	106.6	(91.5-123.5)
Female	2	1.1	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	26	22.8	113.9	(74.4-166.9)					
Female	29	22.5	129.1	(86.4-185.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wilbraham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	17	19.0	89.4	(52.0-143.1)	Male	15	11.5	130.9	(73.2-215.9)
Female	13	6.8	190.0	(101.1-325.0)	Female	11	8.7	126.8	(63.2-227.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	3.4	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	15	9.9	151.6	(84.8-250.0)
Female	82	64.5	127.2	(101.2-157.9)	Female	15	8.7	172.9	(96.7-285.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	2.5	nc	(nc-nc)	Male	3	7.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	20	25.1	79.6	(48.6-123.0)	Female	10	6.6	152.6	(73.1-280.6)
Female	31	24.0	129.1	(87.7-183.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	4	5.8	nc	(nc-nc)
Male	2	4.9	nc	(nc-nc)	Female	7	6.0	117.6	(47.1-242.3)
Female	1	1.3	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	83	70.4	117.9	(93.9-146.1)
Male	3	1.3	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.0	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	2.7	nc	(nc-nc)
Male	8	9.1	88.0	(37.9-173.3)	<b><u>Testis</u></b>				
Female	6	5.3	113.2	(41.3-246.4)	Male	2	1.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	2.9	nc	(nc-nc)	Male	4	3.0	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	10	9.0	110.7	(53.0-203.7)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	8	6.3	128.0	(55.1-252.2)	Female	14	14.4	97.0	(53.0-162.8)
Female	2	4.7	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	224	247.2	90.6	(79.1-103.3)
Male	3	4.6	nc	(nc-nc)	Female	257	227.7	112.9	(99.5-127.6)
Female	4	1.6	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	16	34.6	46.2	(26.4-75.0)					
Female	21	32.6	64.4	(39.8-98.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Williamsburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	3.2	nc	(nc-nc)	Male	0	2.0	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.7	nc	(nc-nc)
Female	14	10.6	132.5	(72.4-222.2)	Female	2	1.3	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	7	4.3	162.6	(65.2-335.1)	Female	2	1.0	nc	(nc-nc)
Female	5	3.3	150.6	(48.5-351.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	2	0.8	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.2	nc	(nc-nc)	Male	11	11.7	94.2	(47.0-168.6)
Female	1	0.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	0	1.5	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	0	1.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	1	0.8	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	7	5.7	122.7	(49.2-252.8)	Male	41	41.7	98.3	(70.5-133.4)
Female	4	4.8	nc	(nc-nc)	Female	43	35.1	122.5	(88.7-165.0)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Williamstown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	11.1	72.2	(31.1-142.3)	Male	10	6.1	164.4	(78.7-302.4)
Female	0	4.7	nc	(nc-nc)	Female	7	5.2	135.8	(54.4-279.8)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	1.7	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	1	0.3	nc	(nc-nc)	Male	7	5.4	128.7	(51.6-265.2)
Female	30	36.4	82.4	(55.6-117.6)	Female	8	5.8	137.7	(59.3-271.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	1.3	nc	(nc-nc)	Male	2	3.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	9	14.0	64.5	(29.4-122.4)	Female	3	4.0	nc	(nc-nc)
Female	16	17.1	93.7	(53.5-152.1)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	3	2.6	nc	(nc-nc)	Male	0	3.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	4.2	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	1	0.9	nc	(nc-nc)	Male	67	36.0	185.9	(144.1-236.1)
Female	1	0.8	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	1	4.6	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	1.5	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	5	3.6	139.4	(44.9-325.3)	Male	1	1.4	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	2.3	nc	(nc-nc)	Female	9	8.1	111.7	(51.0-212.0)
Female	0	1.0	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	20	19.2	104.2	(63.6-160.9)	Male	152	133.6	113.7	(96.4-133.3)
Female	27	21.0	128.6	(84.7-187.1)	Female	130	141.8	91.7	(76.6-108.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wilmington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	20	19.9	100.5	(61.4-155.2)	Male	17	13.6	125.0	(72.8-200.1)
Female	6	7.4	81.0	(29.6-176.2)	Female	10	11.0	90.8	(43.5-166.9)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	4.4	nc	(nc-nc)	Male	4	3.2	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	9	11.5	78.3	(35.7-148.7)
Female	101	77.3	130.6	(106.4-158.8)	Female	10	9.8	102.3	(49.0-188.2)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	3.5	nc	(nc-nc)	Male	4	8.4	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	33	27.3	120.9	(83.2-169.8)	Female	11	7.7	142.9	(71.2-255.7)
Female	25	25.8	97.1	(62.8-143.3)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	6.2	nc	(nc-nc)
Male	5	5.5	91.2	(29.4-212.7)	Female	10	6.3	158.0	(75.6-290.6)
Female	1	1.4	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	92	79.3	116.0	(93.5-142.3)
Male	3	2.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	3	2.8	nc	(nc-nc)
Male	15	10.6	141.6	(79.2-233.6)	<b><u>Testis</u></b>				
Female	6	6.2	97.4	(35.6-212.0)	Male	2	3.4	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	4	3.3	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	13	13.0	100.3	(53.3-171.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	7	7.3	96.4	(38.6-198.7)	Female	21	17.1	122.5	(75.8-187.3)
Female	9	5.5	163.1	(74.4-309.6)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	302	278.4	108.5	(96.6-121.4)
Male	3	5.3	nc	(nc-nc)	Female	304	265.4	114.5	(102.0-128.2)
Female	4	1.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	50	37.2	134.3	(99.7-177.1)					
Female	43	36.2	118.9	(86.0-160.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Winchendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	8	8.8	90.7	(39.0-178.7)	Male	3	6.1	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	2	4.8	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	2.0	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	Female	3	1.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	3	5.1	nc	(nc-nc)
Female	28	33.1	84.6	(56.2-122.3)	Female	4	4.2	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	1.5	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	13	12.1	107.0	(56.9-183.0)	Female	7	3.3	211.5	(84.7-435.8)
Female	3	11.1	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	3	2.8	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	38	34.7	109.4	(77.4-150.2)
Male	0	0.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	0.7	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	1.2	nc	(nc-nc)
Male	4	4.7	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	3	2.7	nc	(nc-nc)	Male	4	1.5	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	5.7	nc	(nc-nc)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	3	3.3	nc	(nc-nc)	Female	9	7.3	123.7	(56.4-234.8)
Female	2	2.4	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	126	123.2	102.3	(85.2-121.8)
Male	3	2.3	nc	(nc-nc)	Female	103	114.3	90.1	(73.6-109.3)
Female	0	0.8	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	20	16.3	122.4	(74.8-189.1)					
Female	19	15.5	122.8	(73.9-191.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Winchester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	35	28.2	124.2	(86.5-172.8)	Male	21	16.8	124.8	(77.2-190.8)
Female	4	11.1	nc	(nc-nc)	Female	14	13.6	102.9	(56.2-172.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	10	5.0	199.4	(95.5-366.8)	Male	3	4.3	nc	(nc-nc)
Female	5	4.3	116.8	(37.7-272.7)	Female	3	3.5	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	0.8	nc	(nc-nc)	Male	16	14.6	110.0	(62.8-178.6)
Female	106	99.6	106.5	(87.2-128.8)	Female	14	13.9	100.4	(54.8-168.5)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	3	3.8	nc	(nc-nc)	Male	10	10.1	98.9	(47.4-182.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	16	36.9	43.3	(24.7-70.4)	Female	10	10.3	97.5	(46.7-179.4)
Female	32	39.5	81.0	(55.4-114.4)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	6	8.5	70.4	(25.7-153.2)
Male	3	7.1	nc	(nc-nc)	Female	5	9.7	51.6	(16.6-120.5)
Female	3	2.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	94	101.7	92.5	(74.7-113.2)
Male	1	1.9	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.5	nc	(nc-nc)	Male	3	6.5	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	4.5	nc	(nc-nc)
Male	18	13.2	136.5	(80.9-215.8)	<b><u>Testis</u></b>				
Female	5	8.3	60.3	(19.4-140.6)	Male	3	2.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	6	4.2	141.5	(51.7-307.9)	Male	8	4.4	183.8	(79.1-362.2)
Female	0	1.2	nc	(nc-nc)	Female	18	13.8	130.3	(77.2-205.9)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	9	9.3	96.7	(44.1-183.6)	Female	27	22.0	122.5	(80.7-178.2)
Female	7	7.6	91.9	(36.8-189.4)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	330	361.3	91.3	(81.7-101.7)
Male	5	6.6	76.2	(24.6-177.9)	Female	333	359.5	92.6	(82.9-103.1)
Female	2	2.5	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	37	50.7	73.0	(51.4-100.6)					
Female	36	51.3	70.2	(49.2-97.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Windsor

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	3.7	135.0	(43.5-315.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male				
Male	0	0.5	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	1	1.7	nc	(nc-nc)	Male	10	12.9	77.6	(37.2-142.8)
Female	0	1.4	nc	(nc-nc)	Female	7	10.9	64.5	(25.8-132.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Winthrop

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	19	20.7	91.9	(55.3-143.4)	Male	22	12.7	172.6	(108.1-261.3)
Female	12	8.2	145.5	(75.1-254.1)	Female	13	10.7	121.1	(64.4-207.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	7	3.8	183.2	(73.4-377.5)	Male	1	3.2	nc	(nc-nc)
Female	1	3.3	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.6	nc	(nc-nc)	Male	16	11.0	145.6	(83.2-236.4)
Female	81	74.9	108.1	(85.9-134.4)	Female	17	10.5	162.3	(94.5-259.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	3.2	nc	(nc-nc)	Male	6	7.5	80.4	(29.4-175.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	23	27.3	84.4	(53.5-126.6)	Female	11	7.7	142.9	(71.2-255.7)
Female	28	29.0	96.5	(64.1-139.5)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	5	6.2	80.1	(25.8-186.8)
Male	9	5.2	172.6	(78.8-327.7)	Female	7	7.2	97.4	(39.0-200.8)
Female	1	1.6	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	71	73.4	96.7	(75.5-122.0)
Male	0	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	1	1.4	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	3.3	nc	(nc-nc)
Male	20	9.8	204.4	(124.8-315.6)	<b><u>Testis</u></b>				
Female	10	6.3	158.5	(75.9-291.5)	Male	3	2.8	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	2	3.1	nc	(nc-nc)	Male	5	3.5	144.1	(46.4-336.2)
Female	0	0.9	nc	(nc-nc)	Female	6	11.6	51.7	(18.9-112.5)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	11	6.9	158.9	(79.2-284.2)	Female	23	16.4	140.6	(89.1-211.0)
Female	4	5.7	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	301	266.8	112.8	(100.4-126.3)
Male	6	4.8	124.5	(45.5-271.0)	Female	302	271.5	111.2	(99.0-124.5)
Female	1	1.9	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	44	37.1	118.7	(86.3-159.4)					
Female	52	38.8	134.0	(100.1-175.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Woburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	38	43.6	87.1	(61.6-119.6)	Male	34	27.2	124.9	(86.5-174.6)
Female	18	16.5	109.3	(64.7-172.7)	Female	22	21.6	101.7	(63.7-154.0)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	5	8.3	60.2	(19.4-140.5)	Male	9	6.7	133.7	(61.0-253.8)
Female	5	6.8	73.7	(23.7-171.9)	Female	6	5.2	116.5	(42.5-253.5)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.3	nc	(nc-nc)	Male	19	23.2	81.8	(49.2-127.7)
Female	179	154.1	116.1	(99.8-134.5)	Female	22	20.8	105.7	(66.2-160.0)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	6.3	78.9	(25.4-184.2)	Male	18	16.0	112.6	(66.7-178.0)
Female					Female	10	7.8	127.7	(61.2-235.0)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	67	57.3	117.0	(90.6-148.5)	Female	9	15.7	57.3	(26.1-108.8)
Female	60	56.0	107.2	(81.8-138.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	21	13.2	158.6	(98.1-242.4)
Male	12	11.2	107.0	(55.2-186.9)	Female	15	14.1	106.5	(59.6-175.7)
Female	2	3.1	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	150	162.1	92.5	(78.3-108.6)
Male	3	3.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	4	2.8	nc	(nc-nc)	Male	8	10.1	79.4	(34.2-156.4)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	1	6.2	nc	(nc-nc)
Male	23	21.1	109.2	(69.2-163.9)	<b><u>Testis</u></b>				
Female	10	12.9	77.4	(37.1-142.4)	Male	3	6.3	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	8	6.7	119.0	(51.2-234.4)	Male	7	7.5	93.0	(37.3-191.6)
Female	1	1.9	nc	(nc-nc)	Female	28	23.7	118.2	(78.5-170.8)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	20	14.7	136.4	(83.3-210.7)	Female	29	34.6	83.8	(56.1-120.3)
Female	12	11.3	106.3	(54.9-185.7)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	595	574.4	103.6	(95.4-112.3)
Male	4	10.3	nc	(nc-nc)	Female	588	549.5	107.0	(98.5-116.0)
Female	3	3.7	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	96	80.4	119.4	(96.7-145.8)					
Female	96	80.3	119.5	(96.8-146.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Worcester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	154	174.8	88.1	(74.8-103.2)	Male	59	108.7	54.3	(41.3-70.0)
Female	65	70.3	92.5	(71.4-117.9)	Female	52	94.3	55.1	(41.2-72.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	25	34.6	72.3	(46.8-106.8)	Male	31	26.7	116.0	(78.8-164.7)
Female	35	30.2	115.9	(80.7-161.1)	Female	14	22.0	63.6	(34.7-106.7)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	5	5.2	96.1	(31.0-224.4)	Male	86	94.6	90.9	(72.7-112.2)
Female	570	633.6	90.0	(82.7-97.7)	Female	99	90.4	109.6	(89.0-133.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	37	27.4	135.2	(95.2-186.4)	Male	50	62.3	80.3	(59.6-105.9)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	236	229.1	103.0	(90.3-117.0)	Female	58	66.2	87.6	(66.5-113.2)
Female	231	248.4	93.0	(81.4-105.8)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					<b><u>Prostate</u></b>				
Male	49	43.3	113.1	(83.7-149.5)	Male	486	606.9	80.1	(73.1-87.5)
Female	15	13.3	112.7	(63.0-185.8)	<b><u>Stomach</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Testis</u></b>				
Male	17	17.3	98.1	(57.1-157.1)	Male	26	29.0	89.6	(58.5-131.3)
Female	9	14.5	61.9	(28.2-117.5)	<b><u>Thyroid</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	63	82.0	76.8	(59.0-98.3)	Female	163	138.5	117.7	(100.3-137.2)
Female	52	53.4	97.3	(72.7-127.6)	<b><u>All Sites / Types</u></b>				
<b><u>Larynx</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	35	25.6	136.6	(95.1-190.0)	Male	2058	2255.1	91.3	(87.4-95.3)
Female	6	7.7	77.8	(28.4-169.2)	Female	2185	2325.5	94.0	(90.1-98.0)
<b><u>Leukemia</u></b>					<b><u>Liver and Intrahepatic Bile Ducts</u></b>				
Male	43	61.7	69.7	(50.4-93.9)	Male	57	40.0	142.3	(107.8-184.4)
Female	42	50.8	82.7	(59.6-111.7)	Female	24	16.1	149.3	(95.7-222.2)
<b><u>Lung and Bronchus</u></b>					<b><u>Lung and Bronchus</u></b>				
Male	340	310.7	109.4	(98.1-121.7)	Male	340	310.7	109.4	(98.1-121.7)
Female	328	328.0	100.0	(89.5-111.4)	Female	328	328.0	100.0	(89.5-111.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Worthington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	3	1.6	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	8	5.4	147.3	(63.4-290.2)	Female	1	0.6	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	0	2.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	6.3	78.8	(25.4-184.0)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male				
Male	2	0.8	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Testis</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
<b><u>Leukemia</u></b>					Male				
Male	0	0.5	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	0	0.4	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Lung and Bronchus</u></b>					Male				
Male	1	3.0	nc	(nc-nc)	Male	15	21.8	68.8	(38.5-113.5)
Female	4	2.3	nc	(nc-nc)	Female	18	17.8	101.0	(59.8-159.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Wrentham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	13	10.6	123.0	(65.4-210.4)	Male	12	7.2	165.8	(85.6-289.7)
Female	10	4.2	235.7	(112.8-433.4)	Female	10	6.0	166.8	(79.8-306.7)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	3	2.3	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	5	6.2	81.3	(26.2-189.6)
Female	37	42.3	87.5	(61.6-120.6)	Female	2	5.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	1.8	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	15	14.8	101.6	(56.8-167.6)	Female	7	4.2	165.0	(66.1-340.0)
Female	23	15.5	148.6	(94.2-223.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	7	3.3	212.8	(85.3-438.5)
Male	3	2.8	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	39	39.9	97.8	(69.5-133.7)
Male	0	1.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
Female	0	0.7	nc	(nc-nc)	Male	0	2.5	nc	(nc-nc)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	2	1.7	nc	(nc-nc)
Male	2	5.6	nc	(nc-nc)	<b><u>Testis</u></b>				
Female	0	3.3	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	0	1.7	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	Female	7	6.7	104.2	(41.7-214.6)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	5	3.9	128.8	(41.5-300.6)	Female	9	8.9	100.7	(45.9-191.1)
Female	4	3.1	nc	(nc-nc)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	143	145.1	98.6	(83.1-116.1)
Male	1	2.8	nc	(nc-nc)	Female	151	147.3	102.5	(86.8-120.2)
Female	1	1.0	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	11	19.0	57.8	(28.8-103.4)					
Female	13	19.6	66.4	(35.3-113.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Yarmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2003-2007

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	77	54.9	140.3	(110.7-175.4)	Male	55	27.6	199.3	(150.1-259.4)
Female	25	19.9	125.5	(81.2-185.2)	Female	30	20.0	149.9	(101.1-214.1)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	7.4	81.2	(29.7-176.8)	Male	8	7.8	102.5	(44.1-202.0)
Female	8	6.4	125.4	(54.0-247.1)	Female	8	6.1	130.1	(56.0-256.4)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	2	1.5	nc	(nc-nc)	Male	28	24.9	112.3	(74.6-162.4)
Female	161	149.2	107.9	(91.9-126.0)	Female	22	23.7	92.6	(58.0-140.3)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	4	4.9	nc	(nc-nc)	Male	14	14.9	93.7	(51.2-157.2)
<b><u>Colon / Rectum</u></b>					<b><u>Ovary</u></b>				
Male	57	67.1	85.0	(64.4-110.1)	Female	16	16.1	99.3	(56.7-161.2)
Female	61	69.3	88.0	(67.3-113.0)	<b><u>Pancreas</u></b>				
<b><u>Esophagus</u></b>					Male	15	15.7	95.4	(53.3-157.3)
Male	13	12.1	107.1	(57.0-183.2)	Female	23	17.5	131.5	(83.3-197.3)
Female	6	3.8	156.9	(57.3-341.6)	<b><u>Prostate</u></b>				
<b><u>Hodgkin Lymphoma</u></b>					Male	222	168.2	132.0	(115.2-150.6)
Male	7	2.5	276.2	(110.6-569.0)	<b><u>Stomach</u></b>				
Female	4	2.0	nc	(nc-nc)	Male	11	12.3	89.2	(44.5-159.7)
<b><u>Kidney &amp; Renal Pelvis</u></b>					Female	9	7.9	113.8	(51.9-216.0)
Male	21	21.3	98.4	(60.9-150.5)	<b><u>Testis</u></b>				
Female	13	13.7	94.8	(50.5-162.2)	Male	2	3.1	nc	(nc-nc)
<b><u>Larynx</u></b>					<b><u>Thyroid</u></b>				
Male	8	7.1	113.4	(48.8-223.4)	Male	6	5.7	104.8	(38.3-228.0)
Female	2	2.0	nc	(nc-nc)	Female	13	17.1	75.9	(40.4-129.8)
<b><u>Leukemia</u></b>					<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Male	15	16.3	92.0	(51.5-151.7)	Female	31	33.4	92.9	(63.1-131.9)
Female	18	12.5	144.0	(85.3-227.6)	<b><u>All Sites / Types</u></b>				
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					Male	721	626.4	115.1	(106.9-123.8)
Male	9	10.2	88.6	(40.4-168.2)	Female	623	581.8	107.1	(98.8-115.8)
Female	2	4.3	nc	(nc-nc)					
<b><u>Lung and Bronchus</u></b>									
Male	94	94.2	99.8	(80.7-122.1)					
Female	99	91.5	108.1	(87.9-131.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;